The Miyamoto Lab focuses on the discovery and development of novel biomarkers to guide the personalized treatment of patients with prostate and bladder cancer. We focus on two general classes of biomarkers, namely those based on the molecular profiles of tumor biopsies, and those based on circulating tumors cells (CTCs) in the blood that can be sampled non-invasively and repeatedly. By analyzing these patient-derived specimens, we have identified new molecular predictors of response to therapy and potential mechanisms of treatment resistance. Our overall aim is to develop tools for “real-time precision medicine” to probe the molecular signatures of cancers as they evolve over time, and to guide the precise and rational selection of appropriate therapies for each individual patient with prostate or bladder cancer.
Do you want to...
Meet current lab members?
Contact the Principal Investigator?
Support our research?
We wish our departing research technicians the very best of luck in their future endeavors. Erika is starting graduate school as a […]
We welcome four new Miyamoto Lab members: Keisuke who joined us in July 2019, Erika and Jake who joined us in August […]
In the podcast Advances at Mass General Cancer Center, Dr. Miyamoto discusses our recent paper in Cancer Discovery on using a digital […]
The Aid for Cancer Research awarded a grant to Dr. Henning Willers and Dr. David Miyamoto to support their research proposal on […]